Skip to content
Homepage
Author:
Tango Therapeutics, Inc.
Posted Date:
June 22, 2026
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics, Inc.
June 22, 2026
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
Tango Therapeutics, Inc.
June 9, 2026
Tango Therapeutics Announces Proposed $500 Million Public Offering
Tango Therapeutics, Inc.
June 8, 2026
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
Tango Therapeutics, Inc.
June 8, 2026
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics, Inc.
June 5, 2026
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Tango Therapeutics, Inc.
May 13, 2026
